Andrew Witty, CEO of pharmaceutical company GlaxoSmithKline, said in a speech Friday at Harvard Medical School that GSK will contribute to a patent pool intended to increase innovation on medicines for neglected diseases. A Reuters story on the event is available here.
Intellectual Property Watch
Original news and analysis on international IP policy
